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The authors present their experience of treating anti-cancer drug extravasation by
means of a composite surgical technique that consists of infiltration with physiological
solution and hyaluronidase and subsequent manual aspiration of solutes alternated
with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a
medical therapy that consists of calciparine and topic antibiotic and/or steroid creams.
Since the year 2000 this technique has been used on 25 patients. We have had neither
complications nor scars.
J. Surg. Oncol. 2005;91:264–269.  2005 Wiley-Liss, Inc.
KEY WORDS: extravasation injury; antiblastic; prevention; treatment
INTRODUCTION
In the last few years, due to an increase in the use of
various chemotherapeutic protocols, we have seen a
directly proportional increase in extravasation injuries.
An ‘‘extravasation injury’’ is usually damage caused
by accidental leakage of solutions from the vein to the
surrounding tissue spaces. The administration of che-
motherapeutic antiblastics involves problems of toxicity
that we do not usually have when dealing with other
drugs.
Chemotherapeutic antiblastics aim at the destruction of
cells. This therapeutic objective is both difficult to eval-
uate and irreversible. Moreover, the treatment is not
selective as regards neoplastic cells so that we can easily
understand what damage it can cause to neighboring
tissues.
Extravasation injuries are among the most dangerous
toxic effects of chemotherapy and they should be avoided
and prevented rather than treated. This is both because
local damage is often serious and because there are no
specific treatments.
Infiltration of the drug in the subcutaneous tissue can
cause damage which can span from light erythema to
serious necrosis. The symptoms of extravasation injuries
which a patient can notice are burning, pain, or intense
paraesthesia which are localised where the infiltration
took place. Other symptoms include reddening, inflam-
mation, swelling, and edema.
Medical literature abounds in works on this topic;
nonetheless there is not a univocal protocol to treat
extravasation injuries yet [1,2]. That is the reason why
different treatments have been used—including topic
hypothermia, infiltration of physiological solution, hya-
luronidase, cortisone creams, antidotes, and even surgical
excision of the ulcer [3–8].
It is worth stressing that, on the basis of different case
reports, in oncological patients who are being submitted
to chemotherapy the incidence of extravasation injuries
varies between 0.5% and 22%. However, there is a
constant increase of 1%–2.5% every year which perhaps
is also due to an increase in the use of chemotherapy in
several oncological protocols.
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Local damage varies depending on the following
parameters:
. Type of drug—vesiculating, exfoliating, irritating or
neutral,
. Quantity of infused drug,
. Area of the infiltration.
Some factors can cause bigger damage; among them it
is worth remembering high osmolarity treatments and
treatments in which the drug can precipitate or closely
bind to cellular structures like DNA, RNA, microtubules.
For the sake of convenience, in order to better devise
treatment, antiblastic drugs are divided into four groups
on the basis of their potential capacity to cause damage to
tissues when extravasation injuries arise:
1. Vesiculating: these drugs can provoke serious cell
damage or destroy tissues (necrosis). They cause bad
andprolongedpains,fibrosis,andlossofmobility(Fig.1).
2. Exfoliating: these are drugs that can cause cell
damage and destruction of the skin tissue; redness
and marked swelling are often immediately apparent,
desquamation develops and progresses to ulcer
formation.
3. Irritating and inflammatory: these drugs, when extra-
vasated, can provoke pains, inflammation, flare
reaction, including redness, either in the area where
they are infused or along the vessel, or ulceration and
rare destruction of the tissues.
4. Neutral: neither inflammatory nor irritating.
As already mentioned, this distinction is made purely
for convenience purposes. Hence we had better consider
each episode of extravasation injury as significant and
worth paying attention to, whatever the drug that pro-
voked it is.
Nowadays, vesiculating antiblastics are the most
dangerous and also the most used injectable substances
(see Table I). Among them there is dexorubicin which
together with other antraciclin drugs is surely one of the
most feared vesiculating drugs because of its capacity to
bind to adipose tissue and, above all, to combine itself
TABLE I. Classification of Antiblastic Drugs on the Basis of the Potential Tissue Damage
They can Cause
Vesiculating:
Group 1
Exfoliating:
Group 2
Irritating and inflaming:
Group 3
Neutral:
Group 4
Amsacrine Aclarubicin Carboplatin Asparaginase
Carmustine Cisplatin Etoposide Bleomicine
Dacarbazine Liposomal daunorubicin Irinotecan Cladribine
Dactinomicine Docetaxel Teniposide Cyclophosphamide
Daunorubicin Liposomal Doxorubicin Phosphate etoposide Cytarabine
Doxorubicin Floxuridine 5-Fluorouracil Edroclomab
Epirubicin Mitrozantrone Methotrexate Fludarabine
Idarubicin Oxaliplatin Gemcitabine
Melphalan Topotecan Ifosfamide
Mitomicin Pentostatin
Mustine Rituximab
Paclitaxel Thiotepa
Streptozocin Beta-interferon
Treosulfan Aldesleukin (IL-2)
Vinblastine
Vincristine
Vindesine
Vinorelbine
Fig. 1. Necrosis 14 days after untreated epirubicin extravasation on
the dorsum of the hand of a 65-year-old man.
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with the DNA in the complex DNA–topoisomerasis II, to
block the synthesis of both DNA and RNA and to provoke
cell death. Other dangerous substances are vincristin,
cisplatin, and vinblastin. All of them at first provoke
severe local inflammation then, after a few days, tissue
ulceration and necrosis.
This article is about our experience of the use of a
conservative surgical protocol combined with a medical
treatment which consists of dilution and aspiration of the
extravasated solute by means of abundant irrigation of the
infiltrated area. Moreover, we will group various aspects
with the aim of finding the right protocol to follow when
dealing with extravasation injuries caused by antiblastic
drugs [9–13].
Our aim is to evaluate the advantages of this treatment
as regards functional and scar outcomes and also the
oncological patient’s quality of life.
SURGICAL TECHNIQUE
Our surgical protocol contemplates four stages:
1. Infiltration
2. First aspiration
3. Washout/irrigation
4. Second aspiration
First of all, this technique contemplates infiltration
of saline solution in subcutaneous tissues where the
extravasation injury is. This operation must be carried
out as soon as possible after the accidental event has
occurred.
The treatment starts by administering intradermic or
subcutaneous local anaesthetic (Ropivacain 7.5%) and
hyaluronidase (Jaluran1 <600 UI). Obviously, the quan-
tity to be injected is directly proportional to the area to
treat and to tissue tension (Fig. 2). During this stage the
aim is to dilute the extravasated drug in order to make
aspiration easier. With the scalpel (Fig. 3), some small
holes in the skin are created (8–10). Through them some
subcutaneous tunnels are created to aspirate the liquid
by means of lipoaspiration cannulas measuring 2 mm
(Fig. 4). Of course, the noble underlying structures
should always be respected (superficial vessels, nervous
fascicles, tendons).
Then, through the skin holes, we carry out a second
infiltration of saline solution which varies between 500
and 3,000 ml—depending on the area—and serves as an
abundant irrigation (Fig. 5). This infiltration is followed
by another aspiration.
The skin holes are never sutured (Fig. 6); they are just
medicated with antibiotic cream and vaselined gauze.
Soft, compressive bandage will then favor further liquid
drainage by means of imbibition and capillarity.
When extravasations injuries take place in the back of
the hand this must be treated with particular care—
fingers are separated by means of gauze in order to avoid
maceration. In the immediate post-op the anti-declivous
position is advised. Finger mobilization is encouraged in
order to favor drainage. In the post-op stage we admi-
nister low dose calciparine (0.3 U.I.) for 2–3 days and
wide-spectrum antibiotics (cephazoline).
Post-op oedemas disappear after 24–40 hr and the skin
holes heal in 4–8 days. We have seen that it is better to
remove and dilute as much extravasated solute as
possible, preferably within 36 hr.
We just carry out hyaluronidase infiltration on patients
who come to us after 48 hr with oedemas or inflammation
or a flush. By contrast, when no clear clinical signs are
present, we do not carry out any treatment but we see the
patient every day for the first week.
Fig. 2. Infiltration of hyaluronidase and physiological solution.
Fig. 3. A 62-year-old woman suffering from doxorubicin extravasa-
tion. The skin holes were done by means of a no. 11 scalpel.
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MATERIALS AND METHODS
Our case report is made-up of 25 oncological
patients that—from January 2000 to date—came to us
within 36 hr of the traumatic event. Fifteen of the patients
are women, while 10 are men whose age ranges between
29 and 72 years (average age 58 years). Presumably, the
quantity of extravasated liquid varied between 10 and
35 mm3.
The time gap which elapsed between the extravasation
and its treatment varies between 100 min and 36 hr.
The most affected areas are the hand back, the wrist
volar fold, the elbow fold, the anti-cubital fossa, the
forearm, and the arm bicipital groove (this is because in
the absence of Implantable Systems—port-a-cath—either
the medial and lateral veins of the forearm—cephalic and
basilic—or the veins on the back of the hand are
cannulated).
The follow-up varies between 8 months and 4 years,
16 months on average. During the observation period we
did not see infections, haematomas, excessive bleeding,
skin paraesthesias, scar retractions, or other significant
complications apart from very small hyperpigmented
areas and one temporary oedema which in any case heal-
ed in a few weeks.
Patients who were treated within a few hours did not
have any inflammation and healed faster. No patients had
difficulty in moving their fingers or wrists. Functionality
was preserved and we did not notice any skin ulcerations
or damage to soft tissues (Fig. 7).
DISCUSSION AND CONCLUSIONS
Extravasations of antiblastic chemotherapeutic drugs
are fortuitous and unpredictable events. Of course, there
are various more or less invasive treatments to choose
Fig. 4. Tunnelling by means of a 2 mm cannula. Aspiration of the
injected liquid.
Fig. 5. Saline flush-out of the extravasation site.
Fig. 6. Immediate post-op.
Fig. 7. Result after 1 month.
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from but they must be carefully considered in relation to
each case. The possibility of developing effective anti-
dotes may help treat this pathology in future.
Sodium bicarbonate, dimetilsulfoxid (DMSO), and
glucocorticoids have been and are still used. They are
certainly useful but they cannot always be administered
and are not always effective.
By contrast, according to F. R. Heckler’s [10] and
J. J. Disa’s [7]studies, the hyaluronidase enzyme seems
to be very useful. It dissolves the binding of hyaluronic
acid in tissues and expands the intra-tissue space thus
creating a wider surface for dilution and for drug
aspiration.
We would like to stress that treatment should be started
as quickly as possible.
This technique is particularly useful for extravasations
of vesiculating and exfoliating antiblastics (see Table I)
and when the quantity of extravasated drug is equal or
above 10 cc.
When dealing with extravasations caused by che-
motherapeutic antiblastic vesiculating, exfoliating, and
irritating drugs we do not agree with the ‘‘wait and see’’
protocol because of high risk of progressively worse
ulcerations and necrosis which often, apart from the skin,
affect the surrounding soft tissues provoking irreversible
damage.
Moreover, the administration of local anaesthetic does
not involve particular side effects in oncological patients.
Extravasation injuries should be considered as onco-
logical medical-surgical emergencies to be treated imme-
diately (within a few hours rather than days) if we want to
limit damage and prevent those severe and disfiguring
ulcerations which lack of treatment can provoke.
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COMMENTARY
Extravasation injury is a well-known adverse event
associated with intravenous chemotherapy administration
and occurs when drugs escape from the veins, catheters or
ports into subcutaneous tissues. The systematic use of
central access catheters and ports has drastically reduc-
ed the incidence of these complications, although they
still occur apparently at the rate of about 0.1%–6% in
patients receiving systemic chemotherapy. The local re-
actions are often distinguished into irritant and vesicant
reactions. The irritant-type are self-limited phlebitis and
erythematous reaction along the vein or at the site of
administration. The reaction by vesicants is often des-
cribed as chemical cellulitis, which initially presents in
a similar way to irritation but may worsen to result in
tissue necrosis. A large number of non-surgical treat-
ments have been attempted such as cold application and
elevation of the affected area with limited success, as well
as local injection of steroids, sodium bicarbonate, sodium
thiosulfate, hyaluronidase, and b-adrenergic agonists
and antagonists. Local application of DMSO has been
tried with some evidence that DMSO protected from
ulceration.
Systemic Dexrazoxane, an agent cardio-protective
from the effects of anthracycline has been found to
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